Search results
Results from the WOW.Com Content Network
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]
Triple-negative breast cancer comprises 15–20% of all breast cancer cases [3] and affects more young women or women with a mutation in the BRCA1 gene than other breast cancers. [4] Triple-negative breast cancers comprise a very heterogeneous group of cancers. TNBC is the most challenging breast cancer type to treat. [5]
Palliative chemotherapy is used to control (but not cure) the cancer in settings in which the cancer has spread beyond the breast and localized lymph nodes. See metastatic breast cancer. Combined therapies These combine, for example, non-drug treatments with localized chemotherapy to limit toxicity and achieve better results. [3]
Invasive carcinoma NST accounts for half of all breast cancer diagnoses in women and is the most common type of invasive breast cancer. It is also the most commonly diagnosed form of male breast cancer. Invasive carcinoma NST is classified by its microscopic, molecular, and genetic features.
This is a list of major breast cancer cell lines that are primarily used in breast cancer research. [Notes 1] List of cell lines. Cell line Primary tumor
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Metastatic breast cancer can be treated, sometimes for many years, but it cannot be cured. [2] Distant metastases are the cause of about 90% of deaths due to breast cancer. [3] Breast cancer can metastasize anywhere in body but primarily metastasizes to the bone, lungs, regional lymph nodes, liver and brain, with the most common site being the ...
Elimination half life: 50.2 h – 54.5 h [b] Dose: Single dose at 60 mg/m 2. Peak plasma concentration: 16 μM Elimination half life: 16.4 h [c] [37] [56] Clinical indication AIDS-related Kaposi's sarcoma, recurrent ovarian cancer and metastatic breast cancer Metastatic breast cancer [21]